SABCS 2025

Important new data for young breast cancer patients

Where is the future of SERDs in MBC?

Axilla dissection - less is more

SERDs now in adjuvant therapy

SERDs in early breast cancer - the new era has begun?

Therapy optimization: Endocrine approaches in…

Revolution in adjuvant endocrine therapy?

Surgery remains soc in low risk EBC

Giredestrant will replace current adjuvant therapy

ALTTO trial outcome according to endocrine therapy

PALLAS trial and ctDNA

Quality of live data DB11

sTILs with deep learning AI

ctDNA analysis could optimize the approach in HER2+

Optimized endocrine therapy for premenopausal patients

Significant innovations in early and metastatic HER2+…

Platinum adjuvant in TNBC

Carboplatin in adjuvant setting of TNBC

Olaparib neoadjuvant with high PCR rates

Otimização da terapia: abordagens endócrinas em…

SERDy we wczesnym raku piersi -początek nowej epoki?

Risultati dello studio ALTTO in base alla terapia…

Carboplatino nel contesto adiuvante del TNBC

La chirurgia rimane lo standard di cura nei casi di…

No improvement over standard therapy

Updated results of VIKTORIA-1

ASCENT-07 a negative trial

Palbociclib likely delays CNS progression

Elacestrant is a good combination partner for HR+ HER2+…

Phase 2 combination of elacestrant with everolimus or…

Traditional chemotherapy should not be forgotten as…

Make a hot tumor out of a cold tumor

Biomarker and clinical subgroup analysis of evERA…

Chemotherapy-free treatment: a promising therapeutic…

Elacestrant as oral endocrine backbone

The significance of SG is more clearly defined

Maintenance therapy HER2+ Tucatinib as a new option

New evidence for oral SERDs

Monitoring of ILD

CDK4/6 inhibitor + endocrine therapy remains the…

Tucatinib a new SERD in the adjuvant setting

ctDNA Dynamics as a biomarker of response

Résultats actualisés de VIKTORIA-1

Risultati aggiornati di VIKTORIA-1

Tucatinib, un nouveau SERD dans le cadre d'un…

Elacestrant come partner endocrino orale

Nuove prove a favore dei SERD orali

Sem melhorias em relação à terapia padrão

La dinamica del ctDNA come biomarcatore di risposta